Evidence map›Paper›PMID 31167564›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2019

MARK4 (Microtubule Affinity-Regulating Kinase 4)-Dependent Inflammasome Activation Promotes Atherosclerosis-Brief Report.

Marc Clement, Xiao Chen, Hannah L Chenoweth, Zhongzhao Teng, Sarah Thome, Stephen A Newland, James Harrison, Xian Yu, Alison J Finigan, Ziad Mallat and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Role of MARK4 in methamphetamine-induced acute kidney injury.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Marc ClementFrom the Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (M.C., H.L.C., S.T., S.A.N., J.H., X.Y., A.J.F., Z.M., X.L.).
Xiao ChenDepartment of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China (X.C.).
Hannah L ChenowethFrom the Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (M.C., H.L.C., S.T., S.A.N., J.H., X.Y., A.J.F., Z.M., X.L.).
Zhongzhao TengDepartment of Radiology, University of Cambridge, United Kingdom (Z.T.).
Sarah ThomeFrom the Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (M.C., H.L.C., S.T., S.A.N., J.H., X.Y., A.J.F., Z.M., X.L.).
Stephen A NewlandFrom the Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (M.C., H.L.C., S.T., S.A.N., J.H., X.Y., A.J.F., Z.M., X.L.).
James HarrisonFrom the Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (M.C., H.L.C., S.T., S.A.N., J.H., X.Y., A.J.F., Z.M., X.L.).
Xian YuFrom the Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (M.C., H.L.C., S.T., S.A.N., J.H., X.Y., A.J.F., Z.M., X.L.).
Alison J FiniganFrom the Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (M.C., H.L.C., S.T., S.A.N., J.H., X.Y., A.J.F., Z.M., X.L.).
Ziad MallatFrom the Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (M.C., H.L.C., S.T., S.A.N., J.H., X.Y., A.J.F., Z.M., X.L.).
Xuan LiFrom the Division of Cardiovascular Medicine, University of Cambridge, United Kingdom (M.C., H.L.C., S.T., S.A.N., J.H., X.Y., A.J.F., Z.M., X.L.).
University of Cambridge · GBHuazhong University of Science and Technology · CN

Funding

British Heart Foundation FS/14/28/30713British Heart Foundation FS/17/5/32531British Heart Foundation RG/15/11/31593
6 · The paper itself

Abstract

objectiveMARK4 (microtubule affinity-regulating kinase 4) regulates NLRP3 (nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain containing 3) inflammasome activation. The aim of the study is to examine the role of MARK4 in hematopoietic cells during atherosclerosis. METHODS AND

resultsWe show increased MARK4 expression in human atherosclerotic lesions compared with adjacent areas. MARK4 is coexpressed with NLRP3, and they colocalize in areas enriched in CD68-positive but α-SMA (α-smooth muscle actin)-negative cells. Expression of MARK4 and NLRP3 in the atherosclerotic lesions is associated with the production of active IL (interleukin)-1β and IL-18. To directly assess the role of hematopoietic MARK4 in NLRP3 inflammasome activation and atherosclerotic plaque formation, Ldlr (low-density lipoprotein receptor)-deficient mice were lethally irradiated and reconstituted with either wild-type or Mark4-deficient bone marrow cells, and were subsequently fed a high-fat diet and cholesterol diet for 9 weeks. Mark4 deficiency in bone marrow cells led to a significant reduction of lesion size, together with decreased circulating levels of IL-18 and IFN-γ (interferon-γ). Furthermore, Mark4 deficiency in primary murine bone marrow-derived macrophages prevented cholesterol crystal-induced NLRP3 inflammasome activation, as revealed by reduced caspase-1 activity together with reduced production of IL-1β and IL-18.

conclusionsMARK4-dependent NLRP3 inflammasome activation in the hematopoietic cells regulates the development of atherosclerosis.

Indexed as

AgedAged, 80 and overAnimalsAtherosclerosisCells, CulturedHumansInflammasomesInterleukin-18MaleMiceMice, Inbred C57BLMiddle AgedNLR Family, Pyrin Domain-Containing 3 ProteinProtein Serine-Threonine KinasesReceptors, LDLInflammasomesInterleukin-18MARK4 protein, humanNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanProtein Serine-Threonine KinasesReceptors, LDLatherosclerosisbone marrow cellsinflammasomeinflammationMARK4microtubulesNLRP3

Identifiers

PMID31167564
OpenAlexW2954489340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.